Aclarion Inc

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BROOMFIELD, CO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Thursday January 4, 2024, it will complete a 1-for-16 reverse stock split of its common stock.

Aclarion Announces Reverse Stock Split

Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel of 10 Key Opinion Leader (KOL) surgeons All commercial Nociscans to date have been completed on Siemens MRI scanners with additional acceleration of volumes expected as Philips scanners are onboarded BROOMFIELD, CO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has completed 1,000 commercial Nociscan exams. “The milestone by itself is significant, but the pace of our commercial adoption is the most exciting aspect of achieving 1,000 commercial scans,” stated Brent Ness, CEO of Aclarion.

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian Och Spine.

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023.

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Partnership aims to include Aclarion's Nociscan surgical decisioning technology within ATEC's AlphaInformatiX platform to better inform spine surgery

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

BROOMFIELD, CO, Aug. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it was not able to file its Quarterly Report for the quarter ended June 30, 2023 by the August 21, 2023 extended filing deadline established by the Securities and Exchange Commission. The Company, therefore, is a late filer with respect to such report.

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

BROOMFIELD, CO, June 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –  Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their commercial agreement with The Imaging Center in Grand Rapids, MI.  The Imaging Center is a new medical imaging center in the greater Grand Rapids market serving physicians who demand core imaging capabilities, as well as innovative solutions like Nociscan.

Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually.

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

The London Clinic is the UK's most renowned independent, private hospital, established 1932. The London Spine Clinic is first specialist spinal unit established in England, 1997.

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

Development of This Program Supports Aclarion's Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key Opinion Leader Advocacy

Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will not file its Quarterly Report for the quarter ended March 31, 2023 within the filing deadline established by the Securities and Exchange Commission and will be a late filer with respect to such report.

Aclarion, Inc. Announces Delayed 10-Q Filing

Up to $2M Unsecured, Non-Convertible Bridge Debt With No Required Amortization Payments Financing Supports Execution of the 2023 Plan and the Achievement of Critical Milestones in Support of Definitive Growth Capital BROOMFIELD, CO, May 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the closing of up to a $2M unsecured, non-convertible debt financing that allows the Company to continue executing on its 2023 plan while providing the runway to achieve three critical milestones ahead of securing definitive growth capital. Brent Ness, CEO of Aclarion, said, “We have been executing really well on multiple fronts.

Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts

Nociscan™ is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological low back pain.

Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023

Aeglea BioTherapeutics

Astra Space

Bionano Genomics

Credit Suisse

Getaround Inc

Canoo

Inpixon

Tempo Automation Holdings Inc

VirnetX

Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch Under $1

Aclarion shares skyrocketed after the company published data from a two-year trial that demonstrated improved surgical outcomes for discogenic lower back pain (DLBP) surgeries at chemically painful lumbar discs identified by Nociscan, the company's intelligence platform for measuring pain biomarkers in the lumbar spine. Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine and uses its proprietary signal processing techniques to extract and quantify chemical biomarkers associated with disc pain, according to Aclarion.

Aclarion skyrockets on positive trial data for lower back pain intelligence platform

Penny stocks to watch under $1 this week. The post Penny Stocks to Buy Now?

Penny Stocks to Buy Now? 7 Under $1 To Watch This Week

Broomfield, CO, March 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Alpesh Patel, MD, MBA Co-Director of Northwestern Center for Spine Health will advise the company as a key opinion leader (KOL). In addition to his leadership role in the Center for Spine Health, Dr. Patel serves as professor of Orthopaedic Surgery and Neurosurgery at Northwestern University in Evanston, IL.

Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor

BROOMFIELD, CO / ACCESSWIRE / February 16, 2023 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), has been invited to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21st - 24th, 2023. Jeff Thramann, Executive Chairman, will present at the conference.

Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023

NociscanTM  is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain.

Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium

Broomfield, CO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Gregory Basil, MD, Director of Endoscopic Spine Surgery at the University of Miami will advise the company as a key opinion leader (KOL). Dr. Basil is an award-winning surgeon with particular interest in clinical outcomes through novel, objective innovations. Dr. Basil is also an entrepreneur and co-founder of Kinesiometrics.

Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor

Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL). Dr. Frey is a renowned surgeon and inventor with dozens of US and worldwide patents in medical devices, technologies, and methods. Dr. Frey's experiences as a clinician and entrepreneur will provide valuable direction to Aclarion.

Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

Broomfield, Colorado--(Newsfile Corp. - January 17, 2023) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"),  a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting virtually at the upcoming Virtual Investor Summit on January 26th.Event: Q1 Investor SummitDate: January 26th, 2023Presentation: January 26th at 12:30 pm ET timeLocation: https://us06web.zoom.us/webinar/register/WN_IyxNcENWRd-KCIMWYg6F6w

Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event

Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire  -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Dr. Christopher Ames, Director of Spinal Deformity and Spine Tumor Surgery and Co-Director of the Combined High Risk Spine Service, the Neurospinal Disorders Program, and the UCSF Spine Center at the University of California at San Francisco will advise the company as a Key Opinion Leader (KOL) nationally.

Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor

Development of this program supports Aclarion's commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy.

News for Aclarion Inc Stock (ACON)